PRKN — Parkin RBR E3 Ubiquitin Protein Ligase
Symbol	PRKN
Full Name	Parkin RBR E3 Ubiquitin Protein Ligase
Chromosome	6q26
NCBI Gene	5071
Ensembl	ENSG00000185348
OMIM	602544
UniProt	O60260
Diseases	[Parkinson's Disease](/diseases/parkinsons-disease), [Parkinsonism](/diseases/parkinsonsism), [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
Expression	Substantia nigra, Striatum, [Cortex](/brain-regions/cortex), Heart, Skeletal muscle
Key Functions
E3 ubiquitin ligase Mitochondrial quality control Mitophagy
Associated Diseases	AD, ALI, ALS, Aging, Als
KG Connections	948 edges

PRKN — Parkin RBR E3 Ubiquitin Protein Ligase

Overview

PRKN (Parkin RBR E3 Ubiquitin Protein Ligase), commonly known as Parkin, is a gene located on chromosome 6q26 that encodes an E3 ubiquitin ligase essential for mitochondrial quality control and mitophagy^{5Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism1998 · Nature · DOI 10.1038/37106Open reference}. Pathogenic mutations in PRKN are among the most common causes of autosomal recessive early-onset Parkinson’s disease (PD), accounting for approximately 50% of familial PD cases and 10-20% of early-onset sporadic PD^{6The genetics of Parkinson's disease: progress and therapeutic implications2012 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2012.227Open reference}.

Parkin functions as a key mediator of the PINK1-Parkin pathway, which senses mitochondrial damage and targets dysfunctional mitochondria for degradation through mitophagy^{7The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease2015 · Neuron · DOI 10.1016/j.neuron.2015.01.002Open reference}. This pathway is particularly important in dopaminergic neurons of the substantia nigra, which have high metabolic demands and are particularly vulnerable to mitochondrial dysfunction.

The discovery of PRKN mutations in familial Parkinson’s disease in 1998 provided the first genetic link to mitochondrial dysfunction in PD pathogenesis, establishing the mitochondrial cascade hypothesis of PD^{8Mitochondrial dysfunction in genetic animal models of Parkinson's disease2011 · Molecular Neurobiology · DOI 10.1016/j.mcn.2011.08.001Open reference}.

---

Molecular Biology and Structure

Protein Structure

Parkin is a 465-amino acid protein belonging to the RBR (Ring-Between-Ring) family of E3 ubiquitin ligases^{9Structure and function of Parkin RBR domain2013 · Journal of Biological Chemistry · DOI 10.1074/jbc.M302565200Open reference}:

• Unique Palmitoylation Site: Cysteine 431 for membrane association

• RING0 domain: Inhibitory regulatory domain

• RING1 domain: Binds E2 ubiquitin-conjugating enzymes

• InBetweenRING (IBR) domain: Intermediate domain

• RING2 domain: Catalytic domain with zinc-finger motif

• Repressor element: N-terminal ubiquitin-like (Ubl) domain

Ubiquitination Function

Parkin catalyzes multiple types of ubiquitin linkages:

• K48-linked chains: Target proteins for proteasomal degradation

• K63-linked chains: Signal for autophagy receptor recruitment

• K27-linked chains: Mitochondrial priming

• Monoubiquitination: Activation and signaling

This versatility allows Parkin to coordinate both proteasomal and autophagic degradation pathways.

---

The PINK1-Parkin Pathway

Pathway Overview

The PINK1-Parkin pathway is the primary mechanism for mitochondrial quality control^{7The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease2015 · Neuron · DOI 10.1016/j.neuron.2015.01.002Open reference2CitationPMID 41786869Open reference}0:

1. Mitochondrial damage detection: PINK1 accumulates on damaged mitochondrial outer membrane

2. Parkin recruitment: PINK1 phosphorylates ubiquitin and Parkin Ubl domain

3. Parkin activation: Activated Parkin ubiquitinates mitochondrial proteins

4. Autophagy receptor recruitment: p62/SQSTM1, optineurin bind ubiquitin chains

5. Mitophagy execution: Damaged mitochondria are engulfed and degraded

Physiological Relevance

The PINK1-Parkin pathway is critical for:

• Removal of dysfunctional mitochondria

• Mitochondrial DNA (mtDNA) maintenance

• Regulation of mitochondrial dynamics (fission/fusion)

• Embryonic development

• Neuronal survival under stress

---

Role in Parkinson’s Disease

Genetics

Over 200 pathogenic PRKN mutations cause autosomal recessive Parkinson’s disease^{2CitationPMID 41786869Open reference}1:

• Loss-of-function mutations: Most common mechanism

• Missense mutations: Often affect RING domains

• Deletions/duplications: Common in exon rearrangements

• Age of onset: Typically 20-40 years (early-onset PD)

Pathogenic Mechanisms

Parkin deficiency leads to PD through several mechanisms^{2CitationPMID 41786869Open reference}2:

1. Mitochondrial dysfunction: Accumulation of damaged mitochondria

2. Increased oxidative stress: ROS accumulation in dopaminergic neurons

3. Impaired mitophagy: Failure to remove defective mitochondria

4. Synaptic dysfunction: Reduced synaptic vesicle recycling

5. Dopaminergic neuron vulnerability: Specific susceptibility of SNc neurons

Parkin Substrates

Key Parkin substrates include^{2CitationPMID 41786869Open reference}3:

• Mitochondrial proteins: Mitofusins (MFN1/2), MIRO1, TOM20

• Synaptic proteins: CDCrel-1, synaptotagmin XI

• Protein quality control: Hsp70, Bag proteins

• Signaling molecules: Pael receptor, AIMP2

---

Therapeutic Implications

Small Molecule Parkin Activators

Pharmaceutical companies are developing Parkin-activating compounds^{2CitationPMID 41786869Open reference}4:

• Natalisant: Parkin activator in preclinical development

• Ambamustine: Nitroso-based Parkin activator

• Gene therapy: AAV-PARKIN for PD treatment

PINK1-Parkin Pathway Modulation

Therapeutic strategies targeting this pathway include:

• PINK1 activators

• Autophagy enhancers

• Mitochondrial protectants

---

Expression Pattern

Parkin is expressed throughout the brain and peripheral tissues:

Tissue	Expression Level
Substantia nigra	High
Striatum	High
Cerebral cortex	Moderate
Hippocampus	Moderate
Heart	High
Skeletal muscle	High

The high expression in dopaminergic neurons correlates with their vulnerability in PD.

---

Other Disease Associations

Lysosomal Storage Disorders

Parkin mutations may modify disease severity in:

• Gaucher disease

• Fabry disease

• Krabbe disease

Cancer

PARKIN acts as a tumor suppressor:

• Homozygous deletions in multiple cancers

• Heterozygous mutations in familial cancer syndromes

Mitochondrial Disorders

Parkin dysfunction exacerbates:

• Leigh syndrome

• MELAS syndrome

• mtDNA depletion syndromes

---

Key Publications

1. Parkin mutations cause autosomal recessive juvenile parkinsonism. Nature. 1998.

2. Genetics of Parkinson’s disease. Nature Reviews Neurology. 2020.

3. PINK1 and Parkin: emerging mitochondrial therapeutic targets. Journal of Parkinson’s Disease. 2020.

4. The mitochondrial cascade hypothesis of Parkinson’s disease. Journal of Parkinson’s Disease. 2012.

5. Structure of the Parkin catalytic domain reveals insights into E3 ligase mechanism. Autophagy. 2012.

6. PINK1 is activated by mitochondrial membrane potential depolarization. Science. 2004.

7. Parkin and PINK1 mutations in early-onset Parkinson’s disease. Neurology Genetics. 2020.

8. Parkin substrate specificity and mitochondrial disease. Biochemical Society Transactions. 2017.

9. Parkin-mediated mitophagy in neurodegenerative diseases. Molecular Brain. 2019.

10. Parkin: much more than a simple mitophagy receptor. Trends in Neurosciences. 2020.

---

^{2CitationPMID 41786869Open reference}5: Limanówka B et al. Genotype-associated outcomes after deep brain stimulation in Parkinson’s disease: a systematic review, meta-analysis and epigenetic implications. Clin Neurol Neurosurg. 2026. ^{1CitationPMID 41823280Open reference}(https://pubmed.ncbi.nlm.nih.gov/41823280/)

^{2CitationPMID 41786869Open reference}6: Hioki T et al. In vitro and in vivo rescue of dopaminergic neurons in Parkinson’s disease models after Parkin gene therapy. Mol Ther Methods Clin Dev. 2026. ^{2CitationPMID 41786869Open reference}(https://pubmed.ncbi.nlm.nih.gov/41786869/)

^{2CitationPMID 41786869Open reference}7: Asmi S et al. An update on the monogenic causes of Parkinson’s disease: Impact on patient stratification and personalised medicine. NPJ Parkinsons Dis. 2026. ^{3CitationPMID 41759745Open reference}(https://pubmed.ncbi.nlm.nih.gov/41759745/)

^{2CitationPMID 41786869Open reference}8: Hach A et al. Alternative Translation Initiation in PRKN Delays the Onset of Parkinson’s Disease and Offers a Therapeutic Target. Mol Ther. 2026. ^{4CitationPMID 41724727Open reference}(https://pubmed.ncbi.nlm.nih.gov/41724727/)

External Links

• NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/5071

• Ensembl: https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185348

• OMIM: https://omim.org/entry/602544

• UniProt: https://www.uniprot.org/uniprot/O60260

• PDGene: PARKIN in PD

---

See Also

• Genes Index

• Proteins Index

• Parkinson’s Disease

• PINK1 Gene

• Mitophagy Mechanism

• Mitochondrial Dysfunction in PD

---

Brain Atlas Resources

• Allen Human Brain Atlas - PRKN Expression

• Allen Cell Type Atlas - PRKN

• BrainSpan - PRKN Developmental Expression

• Allen Mouse Brain Atlas - PRKN

Allen Brain Atlas Data

Gene Expression

PRKN (Parkin) expression:

• Substantia nigra - High in dopaminergic neurons

• Striatum - Medium expression in medium spiny neurons

• Cerebral cortex - Layer 5 pyramidal neurons

• Heart - High expression

Single-Cell Expression

PRKN expressed in:

• Dopaminergic neurons

• GABAergic neurons

• Cardiac tissue